Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abatacept

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

Bristol-Myers Squibb (BMS) building

Opdivo to be tested as ‘double immunotherapy’ for tumours

BMS and Ono to test anti-PD-1 in combination with Kyowa Hakko's mogamulizumab

- PMLiVE

PD-1 inhibitors shine at ASH conference

New data suggests the immunotherapy class could be also used for haematological cancers

- PMLiVE

Pfizer signs $2.85bn immuno-oncology alliance

Will jointly develop Merck KGaA's lead anti-PD-L1 drug

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Bristol Myers Squibb logo

First phase III data for BMS’ anti-PD1 nivolumab

Opdivo shows promise in melanoma study

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links